SG149000A1 - Gag binding proteins - Google Patents

Gag binding proteins

Info

Publication number
SG149000A1
SG149000A1 SG200809009-4A SG2008090094A SG149000A1 SG 149000 A1 SG149000 A1 SG 149000A1 SG 2008090094 A SG2008090094 A SG 2008090094A SG 149000 A1 SG149000 A1 SG 149000A1
Authority
SG
Singapore
Prior art keywords
gag binding
site
gag
binding proteins
protein
Prior art date
Application number
SG200809009-4A
Other languages
English (en)
Inventor
Andreas J Kungl
Original Assignee
Protaffin Biotechnologie Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protaffin Biotechnologie Ag filed Critical Protaffin Biotechnologie Ag
Publication of SG149000A1 publication Critical patent/SG149000A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5421—IL-8
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG200809009-4A 2003-12-04 2004-12-02 Gag binding proteins SG149000A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AT0195203A AT412785B (de) 2003-12-04 2003-12-04 Gag-bindungsproteine

Publications (1)

Publication Number Publication Date
SG149000A1 true SG149000A1 (en) 2009-01-29

Family

ID=33494536

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200809009-4A SG149000A1 (en) 2003-12-04 2004-12-02 Gag binding proteins

Country Status (20)

Country Link
US (4) US7585937B2 (https=)
EP (5) EP2363411A1 (https=)
JP (3) JP4980721B2 (https=)
KR (2) KR101278459B1 (https=)
CN (1) CN1890264B (https=)
AT (3) AT412785B (https=)
AU (1) AU2004295104B2 (https=)
BR (1) BRPI0416544A (https=)
CA (1) CA2546789A1 (https=)
CY (2) CY1109480T1 (https=)
DE (1) DE602004022595D1 (https=)
DK (2) DK1689775T3 (https=)
ES (2) ES2369139T3 (https=)
IL (1) IL175565A0 (https=)
NZ (1) NZ547612A (https=)
PL (2) PL1689775T3 (https=)
PT (2) PT1689775E (https=)
SG (1) SG149000A1 (https=)
SI (2) SI1689775T1 (https=)
WO (1) WO2005054285A1 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT412785B (de) * 2003-12-04 2005-07-25 Kungl Andreas J Dr Gag-bindungsproteine
ES2543341T3 (es) 2005-09-13 2015-08-18 National Research Council Of Canada Métodos y composiciones para modular la actividad de células tumorales
CN100366637C (zh) * 2005-11-17 2008-02-06 中国人民解放军第四军医大学 人白细胞介素8拮抗蛋白及其制备方法
US9422356B2 (en) * 2006-01-31 2016-08-23 Republic Of Korea (Republic Of National Fisheries Research And Development Institute) Artificial signal peptide for expressing an insoluble protein as a soluble active form
CA2822302A1 (en) 2006-02-13 2007-08-23 Alethia Biotherapeutics Inc. Methods of impairing osteoclast differentiation
US8168181B2 (en) 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
EP1894571A1 (en) * 2006-08-29 2008-03-05 Protaffin Biotechnologie AG Use of modified interleukin-8 proteins for treating reperfusion injury or transplant rejection
WO2008140500A2 (en) * 2006-12-08 2008-11-20 The University Of Miami Hyaluronidase inhibitors as anti-cancer agents
AT504685B1 (de) * 2006-12-20 2009-01-15 Protaffin Biotechnologie Ag Fusionsproteine
CA2686817A1 (en) * 2007-05-07 2009-02-19 Peptimmune, Inc. Methods for the directed expansion of epitopes for use as antibody ligands
EP2042516A1 (en) * 2007-09-27 2009-04-01 Protaffin Biotechnologie AG Glycosaminoglycan-antagonising MCP-1 mutants and methods of using same
ES2453592T3 (es) 2007-08-02 2014-04-08 Novimmune Sa Anticuerpos anti-RANTES y métodos de uso de los mismos
EP2053060A1 (en) * 2007-10-24 2009-04-29 Protaffin Biotechnologie AG SDF-1-based glyocosaminoglycan antagonists and methods of using same
US8314212B2 (en) * 2008-02-08 2012-11-20 Lindsey Miles Plasminogen receptor PLG-RKT and antibodies thereof
WO2010086426A1 (en) 2009-01-30 2010-08-05 Protaffin Biotechnologie Ag Glycosaminoglycan-antagonising mcp-i mutants and methods of using same
EP2475380A1 (en) 2009-09-11 2012-07-18 Protaffin Biotechnologie AG Composition for treatment of cxcl8-mediated lung inflammation
EA034462B1 (ru) 2009-11-24 2020-02-11 Алетиа Байотерапьютикс Инк. Антикластериновые антитела и антигенсвязывающие фрагменты и их использование для уменьшения объема новообразований
GB201012603D0 (en) * 2010-07-27 2010-09-08 Ucb Pharma Sa Protein purification
WO2012123585A1 (en) 2011-03-16 2012-09-20 Protaffin Biotechnologie Ag Fgfr1-based antagonists with improved glycosaminoglycan affinity and methods of using same
WO2013007704A2 (en) 2011-07-08 2013-01-17 Protaffin Biotechnologie Ag Novel sdf-1-based glycosaminoglycan antagonist and methods of using same
US9822170B2 (en) 2012-02-22 2017-11-21 Alethia Biotherapeutics Inc. Co-use of a clusterin inhibitor with an EGFR inhibitor to treat cancer
HK1210192A1 (en) 2012-07-19 2016-04-15 Alethia Biotherapeutics Inc. Anti-siglec-15 antibodies
WO2014079957A1 (de) * 2012-11-23 2014-05-30 Bayer Cropscience Ag Selektive inhibition der ethylensignaltransduktion
WO2014109519A1 (ko) * 2013-01-10 2014-07-17 강원대학교산학협력단 작은안구증-연관 전사인자 유래의 펩타이드 및 이를 포함하는 조성물
EP3096776B1 (en) 2014-01-22 2020-12-02 Antagonis Biotherapeutics GmbH Novel glycosaminoglycan-antagonising fusion proteins and methods of using same
US20220281934A1 (en) 2019-08-29 2022-09-08 Antagonis Biotherapeutics Gmbh T-cell mobilizing cxcl10 mutant with increased glycosaminoglycan binding affinity
CN110791523B (zh) * 2019-12-13 2022-05-10 南京农业大学 一种棉花抗旱相关基因GhRCHY1及其应用
KR20250040765A (ko) * 2023-09-15 2025-03-25 (주)케어젠 펩타이드를 유효성분으로 하는 발모 촉진 또는 탈모증의 억제, 예방 또는 개선용 조성물

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4960691A (en) * 1986-09-29 1990-10-02 Abbott Laboratories Chromatographic test strip for determining ligands or receptors
US5234911A (en) * 1990-07-09 1993-08-10 Gist-Brocades, N.V. Substance with interleukin-8 inhibiting activity and process for its preparation
AU8947791A (en) * 1990-11-01 1992-05-26 Scripps Research Institute, The Glycosaminoglycan-targeted fusion proteins, their design, construction and compositions
DK0607777T3 (da) * 1993-01-08 1999-08-16 Hoechst Ag Anvendelse af leflunomid til inhibering af interleukin 8
JP2694321B2 (ja) * 1993-03-10 1997-12-24 大塚製薬株式会社 インターロイキン−１阻害剤
US5527546A (en) * 1994-08-10 1996-06-18 Bayer Corporation Human interleukin 6 inhibitor
US5866402A (en) 1995-05-05 1999-02-02 Chiron Corporation Chimeric MCP and DAF proteins with cell surface localizing domain
JPH1045602A (ja) * 1996-07-31 1998-02-17 Motoyasu Murakami ヘリコバクター・ピロリ接着阻害剤またはインターロイキン−８産生阻害剤
US6852696B2 (en) * 1999-03-26 2005-02-08 The University Of Texas System Inhibitors of glycosaminoglycans
EP2272947B1 (en) 2000-09-05 2016-08-10 Biosight Ltd Peptide conjugated anti-cancer prodrugs
UA77950C2 (en) * 2000-10-04 2007-02-15 Applied Research Systems Use of mutants of cc chemokines for treatment of multiple sclerosis
GB0110430D0 (en) * 2001-04-27 2001-06-20 Medical Res Council Protein variants and uses thereof
JP2003063980A (ja) * 2001-08-28 2003-03-05 Noevir Co Ltd Ｒａｎｔｅｓ産生阻害剤
US6982170B1 (en) * 2001-12-17 2006-01-03 Maine Medical Center Research Institute Compositions, methods and kits relating to thrombin degradation resistant fibroblast growth factor-1
JP2003306438A (ja) * 2002-02-18 2003-10-28 Shiseido Co Ltd ケモカイン発現阻害剤
JP2003267887A (ja) * 2002-03-15 2003-09-25 Shiseido Co Ltd ケモカイン発現抑制皮膚外用剤
IL164376A0 (en) * 2002-04-03 2005-12-18 Applied Research Systems Ox4or binding agents, their preparation and pharmaceutical compositions containing them
AU2003240765A1 (en) * 2002-04-10 2003-10-20 Applied Research Systems Ars Holding N.V. Novel antagonists of mcp proteins
AT412785B (de) * 2003-12-04 2005-07-25 Kungl Andreas J Dr Gag-bindungsproteine

Also Published As

Publication number Publication date
BRPI0416544A (pt) 2007-01-09
US20090005541A1 (en) 2009-01-01
PT1689775E (pt) 2011-10-13
EP1752470B1 (en) 2009-08-12
US20080112926A1 (en) 2008-05-15
CN1890264A (zh) 2007-01-03
DE602004022595D1 (de) 2009-09-24
KR20070001917A (ko) 2007-01-04
JP2012165747A (ja) 2012-09-06
ATE439376T1 (de) 2009-08-15
PL1752470T3 (pl) 2010-01-29
EP1752470A1 (en) 2007-02-14
AT412785B (de) 2005-07-25
WO2005054285A1 (en) 2005-06-16
ES2369139T3 (es) 2011-11-25
US7585937B2 (en) 2009-09-08
SI1752470T1 (sl) 2009-12-31
SI1689775T1 (sl) 2011-11-30
DK1689775T3 (da) 2011-09-26
CY1109480T1 (el) 2014-08-13
ATA19522003A (de) 2004-12-15
NZ547612A (en) 2009-07-31
US7807413B2 (en) 2010-10-05
DK1752470T3 (da) 2009-12-14
JP2012139226A (ja) 2012-07-26
CA2546789A1 (en) 2005-06-16
EP1689775B1 (en) 2011-07-06
PL1689775T3 (pl) 2011-12-30
CY1112330T1 (el) 2015-12-09
US20100331237A1 (en) 2010-12-30
JP4980721B2 (ja) 2012-07-18
ES2330362T3 (es) 2009-12-09
EP2270038A2 (en) 2011-01-05
EP2363411A1 (en) 2011-09-07
US20110144305A1 (en) 2011-06-16
EP2270038A3 (en) 2011-02-23
EP1689775A1 (en) 2006-08-16
KR20120063542A (ko) 2012-06-15
JP2007536906A (ja) 2007-12-20
EP2311866A1 (en) 2011-04-20
IL175565A0 (en) 2006-09-05
AU2004295104B2 (en) 2010-07-22
PT1752470E (pt) 2009-10-15
KR101188785B1 (ko) 2012-10-16
CN1890264B (zh) 2014-01-22
KR101278459B1 (ko) 2013-07-01
ATE515269T1 (de) 2011-07-15
AU2004295104A1 (en) 2005-06-16

Similar Documents

Publication Publication Date Title
SG149000A1 (en) Gag binding proteins
DE60140773D1 (de) Polypeptide zur Bindung an das B-Lymphozyten-stimulatorische Protein (BLyS)
DE60333201D1 (de) Verfahren zur herstellung von proteinen
WO2004081028A3 (en) Allergen peptide fragments and use thereof
AU2003210137A8 (en) Method for producing recombinant proteins in micro-organisms
AU2002310321A8 (en) Compositions and methods for high-level, large-scale production of recombinant proteins
WO2005056585A3 (en) Sars coronavirus s proteins and uses thereof
MXPA03007413A (es) Composicion y metodo para tratar enfermedades inflamatorias.
AU2003273841A1 (en) Method for identifying bhs-specific proteins and fragments thereof
PL1817330T3 (pl) Pochodne alergenów białkowych
WO2006002195A3 (en) Method of complexing a protein by the use of a dispersed system and proteins thereof
WO2002052270A3 (en) Method for identifying substances which positively influence inflammatory conditions of chronic inflammatory airway diseases
AU2003263161A1 (en) Method for making recombinant proteins
DE60325737D1 (de) Verfahren und zusammensetzungen zum targeting sekretorischer lysosomen
WO2006094185A3 (en) Quantification of proteins
DE50115119D1 (de) Verfahren zur aufreinigung von rekombinanten als unlösliche aggregate exprimierte varianten des bet v 1 allergens
WO2004078936A3 (en) Methods for preventing gluconoylation of proteins
EP1181351A4 (en) Method of purifying heterologous proteins
WO2008014296A3 (en) Composition and method for treatment of tumors
AU2003226907A8 (en) Method for the preparation of recombinant mammalian heparin-binding protein (hbp)
DE60218463D1 (de) Untereiheitsimpfstoffe und verfahren zur deren herstellung
DE50309626D1 (de) Verfahren zur vorhersage der expressionseffizienz in zellfreien expressionssystemen
AU2003254630A8 (en) Method for the production of an artificial polypeptide and artificial proteins produced by said method
DE60323062D1 (de) Zubereitung und verfahren zur gewichtsreduktion
AU2002232687A1 (en) Composition and method for improving sexual desire and overall sexual vitality